The landscape of treatments in MPNs like essential thrombocythemia is rapidly changing, with many emerging therapies and drugs in clinical studies. We talk to MPNs specialist, Dr. Ruben Mesa, who helps us translate into laymans’ terms some important updates to watch out for in 2022.

Featuring: Dr. Ruben Mesa, Driector of UT Health San Antonio MD Anderson Cancer Center, Myeloproliferative Neoplasms (MPNs) Specialist

In this Series: Dr. Mesa covers the latest updates following the biggest blood cancer/disease conference (ASH) held at the end of 2021 that looked forward to emerging and promising treatments in clinical trials in 2022 and beyond.

Full story & transcript → [ Ссылка ]

The interview has only been edited for clarity.

Join Our Community:
Website : [ Ссылка ]
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story
____________________________
Contents of this video:

00:00 - Intro
00:58 - The recent history of MPNs and treatments
05:18 - Treatment option for essential thrombocythemia (ET)
9:20 - Access to the ropegylated interferon
10:06 - How would patients get the IMG 7289 or bomedemstat?
11:46 - The promise of not just controlling symptoms but treatment to impact the disease
12:27 - Last message for ET patients and caregivers
____________________________

#ThePatientStory #bloodcancer #blooddisease #hematology #oncology #MPN #myeloproliferativeneoplasms #essentialthrombocythemia #polycythemiavera #clinicaltrials #relapsedrefractory #Patientcare #cancertreatment #Cartcelltherapy

свернуть